Table 3 Associations between rOD of anti-EBV antibodies and primary liver cancer risk by sex, age and classification
EBNA1-IgA | VCA-IgA | |||||||
|---|---|---|---|---|---|---|---|---|
Subgroups | Cases | Controls | Crude OR (95% CI) | Adjusted OR (95% CI)a | Adjusted OR (95% CI)b | Crude OR (95% CI) | Adjusted OR (95% CI)a | Fully adjusted OR (95% CI)b |
Sex | ||||||||
Female | 19 (4.1%) | 445 (95.9%) | 2.02 (0.96,4.26) | 2.10 (0.99,4.48) | 2.14 (0.95,4.83) | 1.70 (0.86,3.35) | 1.71 (0.87,3.36) | 1.57 (0.78,3.18) |
Male | 106 (6.1%) | 1632 (93.9%) | 1.46 (1.11,1.92) | 1.47 (1.11,1.94) | 1.55 (1.13,2.14) | 1.57 (1.02,2.42) | 1.60 (1.04,2.45) | 1.61 (0.98,2.65) |
Age at recruitment, years | ||||||||
30 ~ 39 | 14 (5.6%) | 236 (94.4%) | 5.95 (1.54,22.92) | 5.68 (1.41,22.92) | 5.34 (1.29,22.14) | 1.52 (0.41,5.69) | 1.54 (0.39,6.13) | 1.59 (0.41,6.19) |
40 ~ 49 | 38 (5.5%) | 655 (94.5%) | 1.46 (1.01,2.11) | 1.46 (1.01,2.10) | 1.56 (1.04,2.32) | 2.53 (1.38,4.65) | 2.54 (1.38,4.65) | 2.62 (1.34,5.12) |
50 ~ 59 | 73 (5.8%) | 1186 (94.2%) | 1.43 (0.96,2.11) | 1.43 (0.95,2.14) | 1.46 (0.88,2.41) | 1.28 (0.77,2.13) | 1.30 (0.78,2.15) | 1.17 (0.64,2.12) |
Classification | ||||||||
HCC | 111 (5.9%) | 1777 (94.1%) | 1.45 (1.10,1.92) | 1.46 (1.10,1.93) | 1.51 (1.10,2.09) | 1.66 (1.12,2.44) | 1.68 (1.14,2.48) | 1.66 (1.06,2.60) |
ICC | 14 (4.7%) | 281 (95.3%) | 1.64 (0.83,3.25) | 1.75 (0.85,3.59) | 1.75 (0.82,3.76) | 1.01 (0.28,3.70) | 1.01 (0.28,3.65) | 1.05 (0.30,3.68) |